Pfizer vs Moderna
This page provides a detailed stock comparison between Pfizer Inc. and Moderna, Inc. We explore their distinct business models, analyse their financial performance, and examine their respective market contexts to help you understand the key differences. This analysis is presented in a neutral and accessible manner. Educational content, not financial advice.
This page provides a detailed stock comparison between Pfizer Inc. and Moderna, Inc. We explore their distinct business models, analyse their financial performance, and examine their respective market...
Why It's Moving
Pfizer's Q4 Earnings and 2026 Outlook Spark Debate on Buy, Sell, or Hold Amid Analyst Hold Consensus.
- Q4 EPS hit $0.66, topping estimates and signaling resilient operations despite a 7.8% revenue dip tied to industry competition.
- 2026 adjusted EPS outlook of $2.80-$3.00 matches FactSet consensus at $2.97, underscoring steady profitability ahead.
- Analysts split with 9 buys, 15 holds, and 1 sell, highlighting robust free cash flow of $15B as a buffer for growth initiatives.
Pfizer's Q4 Earnings and 2026 Outlook Spark Debate on Buy, Sell, or Hold Amid Analyst Hold Consensus.
- Q4 EPS hit $0.66, topping estimates and signaling resilient operations despite a 7.8% revenue dip tied to industry competition.
- 2026 adjusted EPS outlook of $2.80-$3.00 matches FactSet consensus at $2.97, underscoring steady profitability ahead.
- Analysts split with 9 buys, 15 holds, and 1 sell, highlighting robust free cash flow of $15B as a buffer for growth initiatives.
Investment Analysis
Pfizer
PFE
Pros
- Pfizer maintains a wide economic moat from its established drug portfolio and brand strength.
- Pfizer offers a high dividend yield of around 6.74% to shareholders.
- Pfizer exhibits low stock volatility of approximately 5.6%, reducing price fluctuation risk.
Considerations
- Pfizer anticipates a 23% decline in its COVID-19 business, pressuring 2026 revenues.
- Pfizer faces a looming patent cliff on key best-selling drugs, risking revenue losses.
- Pfizer trimmed its FY2026 profit forecast to $2.80-$3 per share, below analyst estimates.
Moderna
MRNA
Pros
- Moderna projects 10% revenue growth for 2026, driven by pipeline advancements.
- Moderna holds a healthy current ratio of 3.93, ensuring strong liquidity coverage.
- Moderna anticipates key 2026 catalysts from its Phase III melanoma trial readout.
Considerations
- Moderna reports high stock volatility of nearly 20%, increasing investment risk.
- Moderna experienced a 56% revenue decline over the last twelve months with negative EBITDA.
- Moderna shows a negative gross profit margin of -107.62%, indicating ongoing unprofitability.
Related Market Insights
Pharma Giants: Why Healthcare Stocks Could Weather Any Storm
Invest in Pharma Giants: Discover healthcare stocks offering stability, growth, and recession resistance. Explore innovation & consistent demand in the $1.9T pharma market.
Aimee Silverwood | Financial Analyst
July 25, 2025
Buffett's $6 Billion Donation: The Stocks Set to Benefit
Discover how Warren Buffett's $6B donation creates unique investment opportunities in global health, agriculture & education. Invest via Nemo.
Aimee Silverwood | Financial Analyst
July 25, 2025
Related Market Insights
Pharma Giants: Why Healthcare Stocks Could Weather Any Storm
Invest in Pharma Giants: Discover healthcare stocks offering stability, growth, and recession resistance. Explore innovation & consistent demand in the $1.9T pharma market.
Aimee Silverwood | Financial Analyst
July 25, 2025
Buffett's $6 Billion Donation: The Stocks Set to Benefit
Discover how Warren Buffett's $6B donation creates unique investment opportunities in global health, agriculture & education. Invest via Nemo.
Aimee Silverwood | Financial Analyst
July 25, 2025
Pfizer (PFE) Next Earnings Date
Pfizer's most recent Q4 2025 earnings were reported on February 3, 2026. The next earnings release, covering Q1 2026, is estimated for early May 2026, with consensus pointing to May 4-5, 2026, prior to market open. This aligns with the company's historical quarterly reporting pattern following confirmation of the prior period's results.
Pfizer (PFE) Next Earnings Date
Pfizer's most recent Q4 2025 earnings were reported on February 3, 2026. The next earnings release, covering Q1 2026, is estimated for early May 2026, with consensus pointing to May 4-5, 2026, prior to market open. This aligns with the company's historical quarterly reporting pattern following confirmation of the prior period's results.
Which Baskets Do They Appear In?
Buffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: July 1, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhich Baskets Do They Appear In?
Buffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: July 1, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketBuy PFE or MRNA in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.